Cargando…
The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study
BACKGROUND: Analysis of circulating tumor cells (CTCs) provides real-time measures of cancer sub-populations with potential for CTC-directed therapeutics. We examined whether lapatinib which binds both HER2 and EGFR could induce depletion of the EGFR-positive pool of CTCs, which may in turn lead to...
Autores principales: | Stebbing, Justin, Payne, Rachel, Reise, Justine, Frampton, Adam E., Avery, Miranda, Woodley, Laura, Di Leo, Angelo, Pestrin, Marta, Krell, Jonathan, Coombes, R. Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647066/ https://www.ncbi.nlm.nih.gov/pubmed/23667487 http://dx.doi.org/10.1371/journal.pone.0062543 |
Ejemplares similares
-
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015) -
Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015) -
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015) -
The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?
por: Krell, Jonathan, et al.
Publicado: (2012) -
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
por: Oakman, Catherine, et al.
Publicado: (2010)